Table 2.
Treatments and toxicities.
| Characteristics | Brachytherapy or Observation (G1) |
Radiotherapy +/− Brachytherapy (G2) |
Chemotherapy +/− Radiotherapy +/− Brachytherapy (G3) |
Global | ||||
|---|---|---|---|---|---|---|---|---|
| n = 18 | n = 16 | n = 18 | n = 52 | |||||
| No adjuvant treatment | 10 | 55.6% | 0 | 0.0% | 0 | 0.0% | 10 | 19.2% |
| Adjuvant Brachytherapy | 8 | 44.4% | 13 | 81.3% | 16 | 88.9% | 37 | 71.2% |
| Dose (Gray) | ||||||||
| 6.2 | 0 | 0.0% | 13 | 100.0% | 9 | 56.3% | 22 | 59.5% |
| 24.8 | 8 | 100.0% | 0 | 0.0% | 7 | 43.8% | 15 | 40.5% |
| Toxicity associated with Brachytherapy | ||||||||
| No | 7 | 87.5% | 13 | 100.0% | 16 | 100.0% | 36 | 97.3% |
| Yes | 1 | 12.5% | 0 | 0.0% | 0 | 0.0% | 1 | 2.7% |
| Adjuvant Radiotherapy | 0 | 0.0% | 16 | 100.0% | 11 | 61.1% | 27 | 51.9% |
| Dose (Gray) | ||||||||
| 45 | NA | NA | 13 | 81.3% | 7 | 63.6% | 20 | 74.1% |
| 46 | NA | NA | 0 | 0.0% | 1 | 9.1% | 1 | 3.7% |
| 50 | NA | NA | 0 | 0.0% | 1 | 9.1% | 1 | 3.7% |
| 50.4 | NA | NA | 3 | 18.8% | 2 | 18.2% | 5 | 18.5% |
| Toxicity associated with RT (all toxicities combined) | ||||||||
| No | NA | NA | 8 | 50.0% | 8 | 72.7% | 16 | 59.3% |
| Yes | NA | NA | 8 | 50.0% | 3 | 27.3% | 11 | 40.7% |
| Digestive | 6 | 37.5 | 3 | 27.3% | 9 | 33.3% | ||
| grade 2 | NA | NA | 1 | 6.2% | 0 | 0.0% | 1 | 11.1% |
| Renal and urinary | 4 | 25.0% | 2 | 18.2% | 6 | 22.2% | ||
| grade 2 | NA | NA | 0 | 0.0% | 1 | 9.1% | 1 | 16.7% |
| Gynaecological | 1 | 6.3% | 1 | 9.1% | 2 | |||
| grade 2 | NA | NA | 0 | 0.0% | 1 | 9.1% | 1 | 50.0% |
| Adjuvant chemotherapy | 0 | 0.0% | 0 | 0.0% | 18 | 100.0% | 18 | 34.6% |
| Type of Chemotherapy | ||||||||
| Carboplatin + Taxol | NA | NA | NA | NA | 16 | 88.9% | 16 | 88.9% |
| Cisplatin | NA | NA | NA | NA | 2 | 11.1% | 2 | 11.1% |
| Toxicity associated with CT | ||||||||
| No | NA | NA | NA | NA | 3 | 16.7% | 3 | 16.7% |
| Yes | NA | NA | NA | NA | 15 | 83.3.% | 15 | 83.3.% |
| Hematological | 6 | 33.3% | 6 | 33.3% | ||||
| grade 2 | NA | NA | NA | NA | 3 | 16.7% | 3 | 16.7% |
| grade 3 | NA | NA | NA | NA | 1 | 5.6% | 1 | 5.6% |
| Cutaneous | 14 | 77.7% | 14 | 77.7% | ||||
| grade 2 | NA | NA | NA | NA | 14 | 77.7% | 14 | 77.7% |
| Neurological | 7 | 39.9% | 7 | 39.9% | ||||
| grade 2 | NA | NA | NA | NA | 3 | 16.7% | 3 | 16.7% |
| grade 3 | NA | NA | NA | NA | 1 | 5.6% | 1 | 5.6% |
| Digestive | 2 | 11.1% | 2 | 11.1% | ||||
| grade 2 | NA | NA | NA | NA | 1 | 5.6% | 1 | 5.6% |
| Altered general condition | 7 | 39.9% | 7 | 39.9% | ||||
| grade 2 | NA | NA | NA | NA | 1 | 5.6% | 1 | 5.6% |